Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Piperaquine Tetraphosphate→

Piperaquine Tetraphosphate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
911061-10-4
Molecular formula
C29H44Cl2N6O16P4
Molecular weight
927.5 g/mol
Drug class
Bisquinoline antimalarialblood-schizonticidal agent
Mechanism of action
A bisquinoline antimalarial that interferes with haem detoxification in Plasmodium parasites, leading to accumulation of toxic haem species and parasite death. It is used clinically in combination with dihydroartemisinin; phosphate is a salt component, not a distinct active target.
Indications / reported uses
  • Treatment of uncomplicated Plasmodium falciparum malaria as part of the fixed-dose dihydroartemisinin–piperaquine combination, in accordance with current national malaria guidelines and resistance patterns

Sources: WHO prequalification — Eurartesim product information · EMA EPAR — Eurartesim · WHO Guidelines for malaria

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Bisquinoline antimalarial; blood-schizonticidal agent

Mechanism of action

A bisquinoline antimalarial that interferes with haem detoxification in Plasmodium parasites, leading to accumulation of toxic haem species and parasite death. It is used clinically in combination with dihydroartemisinin; phosphate is a salt component, not a distinct active target.

General use cases

  • Treatment of uncomplicated Plasmodium falciparum malaria as part of the fixed-dose dihydroartemisinin–piperaquine combination, in accordance with current national malaria guidelines and resistance patterns
Active moiety: piperaquine (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

Piperaquine is the antimalarial active moiety; phosphate is the salt component. It is usually used as part of a dihydroartemisinin–piperaquine combination; the combination partner and regimen, not the phosphate counter-ion, determine the combination indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Piperaquine Tetraphosphate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Piperaquine Tetraphosphate Permitted Daily Exposure (PDE) report (the Piperaquine Tetraphosphate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Piperaquine Tetraphosphate Occupational Exposure Limit (OEL) report (the Piperaquine Tetraphosphate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.